Novo Nordisk, Telix Pharmaceuticals And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
U.S. futures rose, but Novo Nordisk fell 4.8% after Cagrisema trial results; Aligos, Telix and other stocks also dropped premarket.
Stocks · News reference
Guggenheim Maintains Buy on Inventiva, Raises Price Target to $14
Guggenheim analyst Seamus Fernandez maintains Inventiva (NASDAQ:IVA) with a Buy and raises the price target from $11 to $14.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Inventiva Completes Final 72-Week NATiV3 Patient Visit With 1,419 Patients Enrolled, Topline Results Expected Q4 2026
Last patient completed final 72-week visit in NATiV3, with 1,009 patients enrolled in the main cohort and 410 patients in the exploratory cohortTopline results of NATiV3 expected in Q4 2026September investor conference
Inventiva Appoints Chris Benecchi As COO